Welcome to our dedicated page for ALMADEN MINERALS SEC filings (Ticker: AAUAF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Almaden Minerals Ltd.’s SEC filings document its reporting as a foreign private issuer that furnishes Form 6-K reports and files annual materials on Form 20-F. The filing record includes audited and interim consolidated financial statements prepared under IFRS Accounting Standards, management’s discussion and analysis, and management certifications for annual and interim filings.
The company’s regulatory documents also furnish meeting and record-date notices, press-release exhibits and governance-related materials associated with shareholder meetings. These filings record Almaden’s financial position, cash flows, changes in equity and formal updates provided to U.S. securities regulators.
Almaden Minerals Ltd. reports developments in its international arbitration claim under the Comprehensive and Progressive Agreement for Trans-Pacific Partnership (CPTPP) against the United Mexican States. The Tribunal has rescheduled the hearing from December 2026 to July 2027, extending its length from six to up to ten days to allow additional time for examination of fact witnesses and experts.
The company also confirms shareholder approval and renewal of its shareholder rights plan at the annual general and special meeting held on June 25, 2026. In addition, under its Stock Option Plan, Almaden granted a director options to purchase 800,000 common shares at an exercise price of $0.27 per share, expiring on August 13, 2031. The news release includes standard cautionary language regarding forward-looking statements related to the arbitration process and associated risks and assumptions.
Almaden Minerals Ltd. reported unaudited results for the three and six months ended June 30, 2026. The company generated no revenue and recorded a net loss of $205,346 for the half-year, much smaller than the $1,193,378 loss in the same period of 2025.
Other income was $852,309, largely from administrative services fees to related companies and foreign exchange gains, while operating expenses declined to $1,057,655 as interest and standby fees on a previously outstanding gold loan ceased. Cash and cash equivalents were $5,930,082 and total assets $6,351,987, with total liabilities of $490,305 and no long-term debt. Working capital was $5,728,545, and management concluded this is sufficient to fund operations for at least the next twelve months.
With title to its former Tuligtic/Ixtaca project revoked, activity now centers on evaluating new opportunities and pursuing compensation from Mexico. Together with Almadex, Almaden is advancing ICSID arbitration under the CPTPP and, based on an updated quantum report, the Claimants seek aggregate damages of US$2.68 billion. Hearings are scheduled for December 2026. A litigation funding agreement provides up to US$9.5 million, of which US$5,079,978 had been disbursed by June 30, 2026; no potential award has been recognized in the financial statements.
Almaden Minerals filed a Form 6-K describing progress in its international arbitration claim against Mexico under the CPTPP. The company and Almadex Minerals have filed their Reply submission with ICSID and now seek aggregate damages of US$2.68 billion related to the Ixtaca precious metals project and royalty.
The Reply incorporates updated independent expert reports, including a quantum analysis reflecting changes in precious metal prices, interest rates and other factors since March 2025. The case is funded through a US$9.5 million non-recourse litigation funding agreement. Mexico’s Rejoinder is scheduled for late August 2026, followed by an in-person hearing in Washington, D.C. on December 14–18, 2026. The company emphasizes that outcomes are uncertain and highlights legal, political and funding risks around the arbitration process.
Almaden Minerals Ltd. has called its 2026 annual general and special meeting for June 25 in Vancouver to elect directors, appoint the auditor, and seek re-approval of its 10% rolling stock option plan and reconfirmation of its shareholder rights plan.
The circular details 137,363,181 common shares outstanding, current director and executive compensation, and outstanding stock options. It also describes key person retention agreements tied to international arbitration over the Ixtaca deposit and notes that Almaden and Almadex are collectively seeking US$2.68 billion in damages, with a hearing scheduled for December.
Almaden Minerals Ltd. reported a much smaller comprehensive loss of $106,606 for the three months ended March 31, 2026, compared with $1,316,336 a year earlier, as financing costs tied to a repaid gold loan dropped and other income improved.
Cash and cash equivalents were $6,064,828 and working capital was $5,798,631, supporting management’s conclusion that the company can fund operations for the next twelve months. The company remains an exploration-stage issuer focused on its international arbitration claim against Mexico under the CPTPP, where it is seeking US$1.06 billion in damages and is funded by a non‑recourse litigation finance facility.
Almaden Minerals Ltd. has filed a report detailing its upcoming Meeting of Security Holders. The Annual General and Special Meeting is scheduled for June 25, 2026 in Vancouver. Shareholders of record as of May 20, 2026 will be entitled to receive notice and vote.
The same date, May 20, 2026, is used as the record date for notice, voting, and beneficial ownership determination. The company will not use notice-and-access for either registered or beneficial holders and will not send proxy materials directly to NOBOs or pay for delivery to OBOs.
Almaden Minerals Ltd. is a Canadian mineral exploration company that currently has no revenue from mining operations and reports under IFRS. It had 137,363,181 common shares outstanding as of December 31, 2025.
After a large non‑cash impairment of the Tuligtic/Ixtaca project in 2023, Almaden reported a net loss of $64,148,145 for 2023, a narrower loss of $2,875,061 for 2024, and net income of $2,989,046 for 2025. The 2025 profit mainly reflects a $4,684,164 gain on the sale of Rock Creek mill equipment and foreign exchange movements, not operating mining income.
The company’s Mexican mineral concessions underlying the Ixtaca project were cancelled by Mexican authorities, leading Almaden and affiliate Almadex to start international arbitration under the CPTPP at ICSID. They are seeking aggregate damages of US$1.06 billion, which Mexico contests, and a three‑person panel has set hearings for December 2026.
Almaden is funding the case through a non‑recourse litigation funding agreement providing up to US$9.5 million; US$4,000,000 had been disbursed by December 31, 2025. The company also realized net proceeds of US$8,245,000 from the Rock Creek asset sale and ended 2025 with working capital of $5,910,941, including cash and cash equivalents of $6,171,157, which management believes is sufficient for the next year.
Almaden remains an exploration‑stage issuer with a history of net losses, no dividend history, and significant risk factors, including reliance on a single major legal claim in Mexico, commodity price volatility, potential shareholder dilution from 11,635,000 outstanding options, and tax and regulatory risks such as possible PFIC classification for U.S. investors.
Almaden Minerals Ltd. reported a strong turnaround in 2025, earning net income of $2,989,046 after losses in 2024 and 2023. The improvement was driven mainly by a $4,684,164 gain on the sale of the Rock Creek Mill and repayment of its gold loan.
Total assets were $6,693,338 at December 31, 2025, with total liabilities reduced sharply to $626,310 after eliminating the $8,128,263 gold loan payable. Cash and cash equivalents rose to $6,171,157, giving working capital of $5,910,941 and supporting the going-concern assessment.
The company continues to focus on international arbitration against Mexico over the revoked Ixtaca mineral concessions. Together with Almadex, it is seeking aggregate damages of US$1.06 billion under the CPTPP, funded by up to US$9.5 million of non-recourse litigation financing, with hearings scheduled for December 2026.